Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines

28 June 2022 | Tuesday | News


Jiangsu Recbio Technology Co., Ltd. is pleased to announce that, the Group has recently received the clinical trial approval (the"Clinical Trial Approval") for its R520A, a mRNA COVID-19 vaccine ("R520A"), from the Food and Drug Administration of the Philippines.
Image Source : Public Domain

Image Source : Public Domain

R520A is an mRNA COVID-19 vaccine specifically targeting the Omicron variant developed by Wuhan Recogen Biotechnology Co., Ltd., a subsidiary of the Company. R520A adopts a self-developed lyophilization technology that can effectively sustain the physiochemical properties and bioactivity of mRNA-LNP and achieve long-term storage at 2℃–8℃. In the pre-clinical studies, the level of neutralizing antibody titers against Omicron variant increased to a high level of 4,758 and it can also induce neutralization response against Delta variant, indicating its promising immunogenicity profile.

The relevant research results have been posted on the preprint server, bioRxiv.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close